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Despite the discovery of 5 alpha-reduction as an enzymatic step in steroid metabolism in 1951, and the discovery that
dihydrotestosterone is more potent than testosterone in 1968, the signiﬁcance of 5 alpha-reduced steroids in human diseases was
notappreciateduntilthediscoveryof5alpha-reductasetype2deﬁciencyin1974.Aﬀectedmalesarebornwithambiguousexternal
genitalia, despite normal internal genitalia. The prostate is hypoplastic, nonpalpable on rectal examination and approximately
1/10th the size of age-matched normal glands. Benign prostate hyperplasia or prostate cancer does not develop in these patients.
At puberty, the external genitalia virilize partially, however, secondary sexual hair remains sparse and male pattern baldness and
acne develop rarely. Several compounds have been developed to inhibit the 5 alpha-reductase isozymes and they play an important
role in the prevention and treatment of many common diseases. This review describes the basic biochemical properties, functions,
tissue distribution, chromosomal location, and clinical signiﬁcance of the 5 alpha-reductase isozyme family.
1.Introduction
Testosterone (T) is the most abundant androgen in serum.
Approximately 97% of T is bound to albumen and sex-
hormone binding globulin and the remaining 3% is free
and biologically active. T is synthesized by the Leydig
cells of the testes under the control of the hypothalamus
and anterior pituitary gland. In male fetuses, T stimulates
the diﬀerentiation of the Wolﬃan duct into male internal
genitalia (epididymis, vas deferens, and seminal vesicles)
and development of libido, enlargement of the vocal cords,
skeletal muscles, penis, and scrotum and the initiation
of spermatogenesis at puberty [1, 2]. T is taken from
circulation to cells through processes that remain poorly
understood. Intracellular T is converted to dihydrotestos-
terone (DHT), the preferred ligand for androgen receptor
(AR) transactivation, by the enzyme 5 alpha-reductase (5α-
R). Upon ligand binding and transactivation, the DHT-
AR complex translocates from cytoplasm to nucleus and
activates the transcription of certain genes (the androgen
receptor-regulated genes, ARRG).
DHT is important for in utero diﬀerentiation and growth
of the prostate gland, male external genitalia (penis and
scrotum), and pubertal growth of facial and body hair.
DHT plays an important role in several human diseases,
whichincludeacne,hirsutism,malepatternbaldness,benign
prostate hyperplasia (BPH), and prostate cancer (CaP) [3].
The role of DHT was discovered after the description of
5α-R2 deﬁciency in a group of males from the Dominican
Republic [4]. DHT has 2–5 times higher binding aﬃnity
for AR than T, and 10-fold higher potency of inducing AR
signaling than T [5], which means that their eﬀects are
diﬀerent but complementary [6].
Three isozymes of 5α-R are known to exist (5α-R1-3) [7]
and two other proteins exhibit 5-alpha reducing capabilities,
glycoprotein synaptic 2 (GPSN2), and glycoprotein synaptic
2-like (GPSN2L) proteins. Only one 5 beta-reductase (5β-
R) enzyme has been identiﬁed. Its products, 5β-isomers,
are labeled as epi-product, such as 5β-DHT (epi-DHT)
[8]. Several compounds have been developed to inhibit the
5α-R enzyme system and they play an important role in
the prevention and treatment of many common diseases
[9]. This review describes the basic biochemical properties,
functions, tissue distribution, chromosomal location, and
clinical signiﬁcance of this enzyme family.2 Advances in Urology
2.Background
Steroids are a special type of lipid. The backbone of steroids
is the compound “gonane”, a 17-carbon molecule composed
of 4 rings. The three cyclohexane rings are labeled A, B,
and C. These 3 rings together are called phenanthrene. Ring
D is a cyclopentane ring. The carbon atoms are numbered
from 1 to 17. Typically, steroids have a methyl group (–
CH3) at carbons C-10 and C-13 and an alkyl side chain
(R) at C-17 (Table 1). Alkanes are saturated hydrocarbons
composed of carbon and hydrogen atoms linked by single
bonds. The simplest alkyl group is a methyl group. Steroids
vary by the conﬁguration of the alkyl side chain, the number
of additional methyl groups, and the functional groups
attached to the steroid nucleus. Carbons number 18 and
19 are attached to carbons number 13 and 10, respectively.
Additional carbon atoms are usually a part of the R side
chain or attached elsewhere to the steroid backbone [22].
Androgens are derivatives of androstane and contain 19 car-
bons and either a keto group (e.g., dehydroepiandrosterone
(DHEA) and androstenedione (ASD)) or a hydroxy group
(e.g., T and DHT) at position 17 of the steroid nucleus
(Figure 1).
3. Historical Overview
Steroid-5-reductases (5α-R and 5β-R) were ﬁrst discovered,
puriﬁed, and characterized in rat liver homogenates [23].
These early experiments demonstrated that these enzymes
were capable of irreversibly reducing the delta 4, 5 bond
(double bond between carbons 4 and 5; Δ4,5)o fC - 1 9a n d
C-21 steroids to 5α-a n d5 β-stereoisomers.
The ﬁrst androgen isolated was androsterone, a 5α-
reduced androstane, which was isolated by Butenant in 1931
from 25,000 liters of urine from adult men. This steroid was
assumed to be the male hormone until 1935 when Ernst
Laquer and his colleagues isolated T from several tons of bull
testes. The 5α-R enzyme was characterized initially in the
1950s in rat liver slices based on its ability to convert deoxy-
corticosterone to 5α-reduced metabolites [24]. Tomkins and
others showed that the enzyme required a reduced pyridine
nucleotide cofactor (i.e., NADPH) and could metabolize a
varietyofsteroidsubstrates[25].Speculationpersistedabout
whether a single enzyme or multiple enzymes were involved
in 5α-reduction of steroids. The 5α-reduction of steroids
made them susceptible to further reduction, sulfation, and
glucuronidation, modiﬁcations that decreased their aﬃnity
tobindproteins,madethemmorehydrophilicandfacilitated
their excretion. In the 1960s, 5α-reduction was shown to
be an irreversible reaction and DHT was found to be a
more potent androgen than T in prostate bioassays [26]. The
administration of radiolabeled T to rats resulted in a time-
dependent accumulation of DHT in the nuclei of ventral
prostatecells,whichsubsequentlyboundtoaspeciﬁcnuclear
(androgen) receptor. These data indicated that 5α-reduction
of T is a crucial step in androgen action and focused
attention on 5α-R. The central role of 5α-R in mammalian
male physiology was obtained from developmental studies
of mammalian embryos showing that 5α-reduction activity
was highest in the primordia of the prostate and external
genitalia prior to their virilization, but very low in Wolﬃan
duct structures [27, 28], and from genetic studies on a rare
disorder of male sexual diﬀerentiation, originally termed
pseudovaginal perineoscrotal hypospadias and subsequently
referred to as 5α-Rdeﬁciency[4].Analysisofenzymeactivity
in skin samples and of urinary and serum steroids revealed a
generalized defect in the conversion of T to DHT.
Studying 5α-R was hampered by the insolubility of the
protein, a hurdle which was overcome in 1989. The tech-
nique of expression cloning in Xenopus laevis oocytes
was used to isolate a cDNA from rat liver that encoded
5α-R enzyme, which was used to isolate a human 5α-R
by cross-hybridization with a prostate cDNA library. The
two expressed proteins had diﬀerent biochemical properties
and diﬀerent responses to ﬁnasteride. These observations
suggested the presence of two 5α-R isozymes that were
conﬁrmed by studies done in patients with 5α-R deﬁciency.
The coding sequence of the gene specifying the rat liver
cDNA was isolated and found to be normal in these patients.
Further genetic studies in these patients identiﬁed a diﬀerent
mutated gene that encoded a 5α-R in normal individuals
with identical biochemical properties to the human prostatic
5α-R. The ﬁrst cDNA, isolated from rat liver, was named
5α-R1 (SRD5A1) gene, and the second cDNA, which was
isolated from human prostate and found defective in 5α-R-
deﬁcient patients, was named 5α-R2 (SRD5A2) gene [29].
More recently, with the development of genome-wide
gene expression proﬁle analyses, a third 5α-R (SRD5A3)
gene was identiﬁed. GPSN2 and GPSN2L proteins were
identiﬁed using sequence searching and NCBI’s BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). All primary species
(from plant, amoeba, yeast, to vertebrate) in Eukaryota
contain all 3 subfamilies [8].
4. FamilyMembers
The5α-Rfamilyiscomposedof3subfamiliesand5members
(isozymes) in total. Isozymes are diﬀerent proteins that per-
form the same function:
(a) 5α-R1 and 5α-R2,
(b) 5α-R3,
(c) GPSN2 and GPSN2L proteins.
5. Functions
5.1. 5 Alpha Reduction: (5α-R1-3) [29, 30]. The substrates
for 5α-reductases are 3-oxo (3-keto), Δ4,5 C 19/C21 steroids.
The group “3-keto” refers to the oxygen-carbon double bond
at carbon 3. Delta 4, 5 refers to the double bond between
carbon atoms 4 and 5. The reaction involves a stereospeciﬁc,
irreversible breakage of the double bond between carbons
4 and 5 (delta 4, 5) with the aid of cofactor NADPH and
the insertion of a hydride anion (H−) to the α face at
carbon C-5 and a proton to the β face at position C-4.
ExamplesofsubstratesareT,progesterone,androstenedione,
epi-T, cortisol, aldosterone, and deoxycorticosterone. TheAdvances in Urology 3
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Figure 1: Structure of various steroids.
physiologic role of 5α-reduction of these steroids (other than
T) is unknown but probably related to their degradation
and excretion or to certain physiologic functions. 5α-
dihydroprogesterone (5α-DHP) is a major hormone in the
circulation of both normal cycling and pregnant women
[31]. 5α-dihydrocortisol is present in the aqueous humor
of the eye, is synthesized in the lens of the eye, and may
play a role in the regulation of aqueous humor formation
[32].5α-Dihydroaldosteroneisapotentantinatriureticagent
with somewhat diﬀerent physiologic eﬀects than aldosterone
itself; its formation in the kidney is enhanced by restriction
of dietary sodium intake, which suggests its importance for4 Advances in Urology
Table 1: Diﬀerent steroid families.
Class Example Number of carbon atoms
Steroid backbone Gonane 17
Estranes Estradiol 18
Androstanes Testosterone 19
Pregnanes Progesterone 21
Glucocorticoids Cortisol 21
Mineralocorticoids Aldosterone 21
Cholanes Cholic acid 24
Cholestanes Cholesterol 27
the conservation of sodium [33]:
(Substrate)+(NADPH)+

H+
−→ (5α-substrate)+

NADP+ (1)
Uemura et al. used small interfering RNA (siRNA) to knock
downtheexpressionof5α-R3isozymein22RV1andLNCaP-
C4-2 CaP cells by transfecting them with several siRNA
expression vectors [34]. Subsequently, they studied mRNA
expression of 5α-R3 (RT-PCR), cell growth and viability,
and the ratio of DHT/T using liquid chromatography-
tandem mass spectrometry.Knockdown of 5α-R3 expression
caused decreased cell growth and viability and DHT/T
ratio. Unpublished work from our group has conﬁrmed
the ability of 5α-R3 to 5α-reduce 3-oxo, delta 4,5 C19
and C21 (T, androstenedione and progesterone) steroids in
lysates of CHO-K1 cells transfected with 5α-R3 cDNA via
an adenovirus vector, CaP cell lines CWR-22 and CWR-
22R, and clinical human samples of androgen-stimulated
benign prostate (AS-BP), androgen-stimulated (AS-CaP),
and castration-recurrent (CR-CaP) CaP.
5.2. N-Glycosylation of Proteins: (5α-R3). Congenital deﬁ-
ciencyof5α-R3hasbeenlinkedtoarare,autosomalrecessive
disorder in which patients are born with mental retardation,
cerebellar, and ophthalmologic defects [35]. The presumed
defect involves the reduction of the terminal double bond
of polyprenols to dolichols, an important step in protein
N-glycosylation. N-linked protein glycosylation involves the
addition of a 14-sugar glycan to select asparagine residues on
a nascent protein to facilitate proper folding and traﬃcking
of the protein and occurs in the membranes of endoplasmic
reticula. This disorder is part of the family of congenital
disordersofglycosylationandwasdescribedfortheﬁrsttime
in a family in the United Arab Emirates by Cantagrel et al.
[35].
5.3. Potential Biomarker of Malignancy: (5α-R1-3) [14, 20].
The bulk of published literature indicates that the expression
of 5α-R1 increases and 5α-R2 decreases in CaP compared to
benign prostate and BPH. Umera et al. conﬁrmed for the
ﬁrst time increased expression of 5α-R3 at the mRNA level
in CR-CaP. Godoy et al., conﬁrmed this at the protein level.
A validated monoclonal antibody showed that expression
of 5α-R3 was increased similarly in AS-CaP and CR-CaP
compared to AS-BP. 5α-R3 expression was increased in lung,
breast, papillary thyroid, and testicular (seminoma and yolk
sac) cancers compared to their benign counterparts.
5.4. Erythropoiesis [36]. 5α-C 19 steroids increase the pro-
duction of erythropoietin hormone in the kidneys. 5β-C 19
steroids are important for heme synthesis in the liver.
5.5.RegulationofBileSynthesis[37]. Both5α-Rand5β-Rare
involved in bile biosynthesis, where they catalyze the conver-
sion of 7α,1 2 α-dihydroxy-4-cholesten-3-one into 7α,12α-
dihydroxy- 5α-cholestan-3-one, and 7α,12α-dihydroxy-5β-
cholestan-3-one, respectively. Only the 5β-isomer has been
shown to be biologically active and is used for bile synthesis.
The 5α-isomer is inactive and suggested to be an inhibitory
step in bile biosynthesis regulation in humans.
5.6. GPSN2 Family [38]. While the functions of the GPSN2
subfamily are not understood fully, several reports have
shown that GPSN2 members are involved in the fourth re-
action of fatty acid elongation by reducing a fatty chain
double bond in mammals. Although the substrate (fatty
acid) of GPSN2 members is structurally diﬀerent from that
oftheothertwo5α-Rsubfamilies,allthreesubfamiliesof5α-
R share a similar biochemical ability of reducing a double
bond of the substrate.
6.ProteinStructureand
GeneLocation[8, 29,39]
5α-R1 and 2 isozymes are NADPH-dependent, membrane-
associated (microsomal) enzymes, composed of 259 and
254 amino acids, and have molecular weights of 29.5 and
28.4 kilodaltons, respectively. They contain a high content
of hydrophobic amino acids distributed throughout their
sequences, which suggests that they are intrinsic membrane
proteins deeply embedded in the lipid bilayer.
Even though these two isozymes are intrinsic membrane
proteins and catalyze the same reaction, they only share a
limited degree of homology in protein sequence, are located
on diﬀerent chromosomes, and possess distinctive biochem-
ical properties. The average sequence identity between these
two isozymes within a given species is approximately 47%,
while the sequence identity between the same isozymeAdvances in Urology 5
across species is 60% for 5α-R1 and 77% for 5α-R2. They
are encoded by the 5α-R1 and 5α-R2 genes. These genes
have similar structures, with ﬁve coding exons separated
by four introns. The positions of the introns are essentially
identical in the two genes. However, SRD5A1 is located
on chromosome 5p15 whereas SRD5A2 is on 2p23. Gene
polymorphisms exist for the two genes and are more
commonfor5α-R2.Morethan850andmorethan550single
nucleotide polymorphisms (SNPs) have been reported for
5α-R2 and 5α-R1 genes, respectively [40, 41]. Only a few
of these gene polymorphisms aﬀect enzyme activity; some
decrease (e.g., V89L SRD5A2 variant) and others increase
(e.g.,A49TSRD5A2variant)enzymeactivity[42].Molecular
epidemiologic studies are inconclusive as to whether altered
5α-R2 isozyme activity due to 5α-R2 gene polymorphism
aﬀects CaP risk [43]. A variant of 5α-R1 gene was reported
to increase risk of polycystic ovary syndrome (PCOS) and
more severe hirsutism in lean women, whereas a variant of
5α-R2genewasassociatedwithdecreasedriskofPCOSinthe
same cohort [44]. More than 300 SNPs have been reported
for 5α-R3 gene; however, their clinical signiﬁcance remains
uncertain [45]. 5α-R3 is composed of 318 amino acids and
hasonly19%homologywith5α-R1and20%homologywith
5α-R2 [39]. 5α-R3 is encoded by SRD5A3, which is located
at 4q12. The genes encoding GPSN2, GPSN2-like, and 5β-
R are located at 19p13.12, 4q13.1, and 7q34, respectively.
GPSN2 and GPSN2-like proteins are composed of 308 and
363 amino acids, respectively. The amino acid sequence
homology for GPSN2 is 15% with 5α-R1, 17% with 5α-R2
and 11% with 5α-R3. GPSN2-like has 6%, 11%, 6%, and
44% sequence homology with 5α-R1, 5α-R2, 5α-R3, and
GPSN2, respectively.
7. Biochemical Properties[8,29]
When examined in lysates of transfected cells, 5α-R1 exhibits
a broad pH optimum, which ranges between 6.0 and 8.5,
while 5α-R2 shows a narrow acidic pH optimum (pH 5–
5.5). However, there is evidence to suggest that inside intact
human cells, 5α-R2 isozyme functions optimally at a more
neutral pH range (6.0–7.0). 5α-R1 has a larger turnover
number, as indicated by its Kcat value and a lower substrate
aﬃnity for T, Km = 1–5μM. 5α-R2 has a lower turnover
number (Kcat) and a higher substrate aﬃnity, as indicated
by Km = 0.004–1μM for T. Under optimal conditions,
5α-R2 has a higher 5α-reducing activity than 5α-R1, as
indicated by its high Vmax/km ratio. Both isozymes contain
an NH2-terminal steroid (ligand) binding domain and a
COOH-terminal NADPH binding domain. The apparent
dissociation constant for NADPH cofactor is similar for
both isozymes (3–10μM). No such comparisons exist for
5α-R3 except that it appears to be eﬃcient at pH 6.5–6.9
(unpublished work from our group).
8. 5α-ReductaseInhibitors[9,30,46]
Goal of development of 5α-reductase inhibitors (5α-RI) was
to bind to 5α-R with little or no aﬃnity for the androgen or
other steroid receptors. The ﬁrst inhibitors were steroids that
mimicked T and, in many cases, were substrates themselves
(i.e., not true inhibitors). The inhibitors can be broadly
classiﬁed into two categories: steroidal and nonsteroidal. The
steroidal class has more inhibitors thus far.
The mechanism of 5α-RI is complex but involves the
binding of NADPH to the enzyme followed by the substrate.
The Δ4,5 bond is broken and a hydride anion is transferred
from NADPH directly to the C-5 carbon on the α face
followed by a proton attacking the C-4 carbon on the β face
leading to the formation of the product that subsequently
leavestheenzyme-NADP+ complex.NADP+ departslastand
theenzymebecomesfreeforfurthercatalysiscycles.Basedon
this,themechanismofinhibitionof5α-Risozymesisdivided
into three types [30]:
(a) competitive with the cofactor (NADPH) and sub-
strate (bi-substrate inhibitors): the inhibitor binds
the free enzyme, for example, ONO-3805;
(b) competitive with the substrate: the inhibitor binds
the enzyme-NADPH complex for example, 4-, 6-,
and 10-azasteroids;
(c) uncompetitive with the enzyme-NADP+ complex:
the inhibitor binds the enzyme-NADP+ complex aft-
er the product leaves, for example, epristeride.
8.1. Steroidal 5α-RI (Figure 1). (1) 4-Azasteroids: the 3-oxo,
5-alpha steroids with a nitrogen atom at position 4 have been
the most extensively studied. Examples include ﬁnasteride
(MK-906), dutasteride (GG745), 4-MA, turosteride, MK-
386, MK-434, and MK-963.
(a) Finasteride is a synthetic 4-azasteroid and is the ﬁrst
5α-RI approved for treatment of benign prostatic
enlargement (BPE) and subsequently male pattern
baldness. Finasteride is a potent (mean inhibitory
concentration [IC50], 69nM) competitive inhibitor
of 5α-R2 but inhibits less eﬀectively 5α-R1 (IC50
360nM)[47].Finasteridedecreasesmeanserumlevel
of DHT by 71% after 24 weeks of use [48]. Seven-day
treatment with ﬁnasteride (1 or 5mg daily) has been
reported to suppress intraprostatic DHT in men with
lower urinary tract symptoms (LUTSs) attributed to
BPE by approximately 85% relative to placebo [49],
whereas another study of ﬁnasteride 5mg/d (also in
men with LUTS attributed to BPE) demonstrated a
r e d u c t i o no f6 8 %a t6m o n t h s[ 49]. Finasteride was
showninvitrotoinhibit5α-R3atasimilarpotencyto
5α-R2 (IC50 = 17.4nM, 14.3nM, resp.) in transfected
HEK-293 cells [21].
(b) Dutasteride is a synthetic 4-azasteroid with a half-life
of nearly 5 weeks and is only approved for treatment
of BPH. Dutasteride is a dual 5α- R Is i n c ei ti sm o r e
eﬀective (more potent) at inhibiting 5α-R1 and 2
than ﬁnasteride; IC50 for inhibiting 5α-R1 is 7nM
and 5α-R2 is 6nM. Dutasteride reduced mean levels
of serum DHT at 24 weeks better than ﬁnasteride
(94.7% versus 70.8% suppression) [50]a n dc a u s e d6 Advances in Urology
a 97% reduction in intraprostatic DHT levels in men
with CaP treated with 5mg/d for 6–10 weeks [51].
Another trial of dutasteride 3.5mg/d for 4 months
prior to RP decreased intraprostatic DHT by 99%
[52]. The near-maximal suppression of intraprostatic
DHT with dutasteride 3.5–5mg daily and the report
that dutasteride inhibits 5α-R3 in vitro (IC50 =
0.33nM)[21]suggestthatthedevelopmentofatriple
5α-Rinhibitormaynotbenecessary.Table 2 provides
a comparison between ﬁnasteride and dutasteride.
(c) 4-MA was a potent dual inhibitor of 5α-R1 (IC50 =
1.7nM) and 5α-R2 (IC50 = 1.9nM). 4-MA had a
very low aﬃnity for AR and thus was not expected
to produce undesirable antiandrogen eﬀects, such
as impotence, impaired muscle growth, or gyneco-
mastia. However, 4-MA was withdrawn from clinical
development after it was shown to be an inhibitor
of 3β-hydroxysteroid dehydrogenase and to cause
hepatotoxicity [9].
(d) Turosteride, MK-434, and MK-963 inhibit mainly
5α-R2. MK-386 is a selective 5α-R1 inhibitor [46].
(2) 6-Azasteroids (e.g., GIlS7669X) have a heterocyclic B
ring (nitrogen atom at position 6) and a Δ4,5 bond in the A
ring and are potent competitive inhibitors of 5α-R1 and 2
[46].
(3) 10-azasteroids, for example, AS97004, are compet-
itive 5α-RI with a similar mechanism of action to 6-azas-
teroids [9].
(4) Androstanecarboxylic acids, such as epristeride, are
noncompetitive, speciﬁc inhibitors for 5α-R2 [30].
(5) Other steroidal inhibitors include progesterone esters
such as 4-bromo-17α-(p-ﬂuorobenzoyloxy)-4-pregnene-3,
20-dione [53], 2-azasteroids, 3-azasteroids, 19-nor-10-azas-
teroids, and diazasteroids [9].
8.2. Nonsteroidal Inhibitors [9, 30, 46]. Several pharmaceu-
tical and academic groups have pursued the synthesis of
nonsteroidal compounds that inhibit human 5α-reductases
due to the undesired hormonal side eﬀects of steroidal com-
pounds. Nonsteroidal inhibitors can be classiﬁed according
to their structure. Most have been derived from azasteroidal
inhibitors by removing one or more rings from the aza-
steroidal structure. Nonsteroidal inhibitors are thought to
act as competitive inhibitors with exception of epristeride
analogues, which are noncompetitive inhibitors. The most
potent and selective inhibitors of human 5α-R1 are found
among these classes of compounds and include the follow-
ing.
(1) Benzoquinolines include many subgroups.
(a) Benzo[f]quinolinones are tricyclic compounds
thatarederivedfrom4-azasteroidsbyremoving
the D ring and substituting the C ring with an
aromatic one. These are selective against 5α-
R1. The potency against 5α-R1 increases by
substituting a halogen atom at position 8 (F, Br,
orspeciallyaCl)andamethylgroupatposition
4. LY 191704 is the most potent (IC50 = 8nM).
(b) Piperidones lack B and D rings.
(c) Quinolinones lack C ring.
(d) Pyridines lack B and C rings.
(e) Benzo[c]quinolinones tricyclic compounds de-
rived from 6-azasteroids (no D ring, aromatic
ring for the C ring) that have selective but weak
inhibitory activity against 5α-R1.
(f) Benzo[c]quinolizinonesaretricycliccompounds
derived from 10-azasteroids (no D ring, aroma-
tic ring for the C ring) that include some very
potent, selective inhibitors of 5α-R1.
(Subgroups (b), (c), and (d)) are very weak 5α-R1I.
(2) Nonsteroidal aryl acids are tricyclic compounds de-
rived from androstanecarboxylic acids that diﬀer
from their parent compounds in being selective,
noncompetitive 5α-R1I.
(3) Butanoic acid derivatives contain an aromatic ring
(generally benzene or indole) that bears a butanoic
acid chain and aromatic moieties. Examples include
ONO-3805, demonstrated in vitro to be a selective
inhibitor of 5α-R1, and FK143, which inhibits 5α-R1
and 5α-R2 equally and noncompetitively.
(4) Polyunsaturated fatty acids, found in vegetable oils,
have been found to inhibit human and rat microso-
mal5α-Ractivity.Inthisgroup,y-linolenicacidisthe
most potent compound tested. Since 5α-R isozymes
are intrinsic membrane proteins, their activity may
depend on the unique environment of the lipid
bilayer. Whether and how fatty acids may function as
endogenous regulators of 5α-R remain unknown.
(5) Some cations, especially zinc, have been reported to
reduce sebum production in vivo and have been used
to treat acne. In vitro assays have indicated that zinc
speciﬁcally inhibits 5α-R1. This inhibition may be
mediated both by non-competitive inhibition of T
binding to 5α-R and by reduced formation of the
NADPH co-factor.
(6) Other nonsteroidal inhibitors include epicatechin-
3-gallate and epigallocatechin-3-gallate, which are
major constituents of green tea. Also included are
7-hydroxycoumarin derivatives, 2,6-disubstituted 4-
hydroxy-4-hydroxymethyl biphenyl derivatives, iso-
ﬂavonoids, and 3,3-diphenylpentane derivatives [9].
9. Tissue Distribution
Numerous reports exist in the literature on the expres-
sion pattern of 5α-R1 and 5α- R 2i nh u m a nt i s s u ea t
various stages of development. The results vary due to
diﬀerences in antibody sensitivity and speciﬁcity, mRNA
analysis(insituhybridizationversusnorthernblottingversus
reverse transcriptase-polymerase chain reaction), protein
analysis (immunohistochemistry versus western blotting),Advances in Urology 7
Table 2: Comparison between ﬁnasteride and dutasteride (referenced in text).
Finasteride Dutasteride
Family Steroidal 5α-RI (4-azasteroid) Steroidal 5α-RI (4-azasteroid)
IC50 for 5α-R1, 2 and 3 (nM) 360, 69, 17.4 7, 6, 0.33
FDA-approved clinical uses Male androgenic alopecia
Benign prostatic enlargement Benign prostatic enlargement
Clinical dose 1mg daily for male androgenic alopecia
5mg daily for benign prostatic enlargement 0.5mg daily
Half-life (T 1/2) 6–8 hours 5 weeks
Suppression of DHT
↓Serum DHT by 71% ↓Serum DHT by 95%
↓Intraprostatic DHT by 85% ↓Intraprostatic DHT by 97–99%
tissue preparation, nature of tissue, evaluation of results,
tissue ﬁxation protocols, and control tissue. In addition,
normal, benign, and malignant human tissue specimens are
heterogeneous with variable expression of proteins among
specimens from diﬀerent individuals and within the same
specimen, that is, inter- and intraindividual variability.
Therefore, a summary of many studies that discussed the
tissue distribution of 5α-R1-3 in diﬀerent human tissues was
tabulated to demonstrate diﬀerences in results (Table 3).
9.1. According to Age
9.1.1. Fetus. Ellsworth and Harris [54] studied 5α-R activity
in fetal scalp, back skin, and prostatic tissues and compared
it to 5α-R activity in adult male scalp and prostatic tissues.
They studied the conversion of radio-labeled T into DHT
in relation to pH and response to selective 5α-R1 and 5α-
R2 inhibitors and calculated the km of T at pH values of
7.0 and 5.5. 5α-R1 is expressed in fetal scalp and nongenital
(back) skin at levels that are 5–50 times less than adult skin.
5α-R2 is expressed in the fetal prostate at levels similar to
adult prostate. Thigpen et al. [13] studied 5α-R expression
in fetal liver, adrenal, testis, ovary, brain, scalp, chest, and
genital skin, using immunoblotting. They detected 5α-R2
only in fetal genital skin. Lunacek et al. [55] studied the
expression of 5α-R 1 and 5α-R2 at the mRNA (RT-PCR) and
protein(immunohistochemistry)levelsinfetalandpostnatal
prostatic tissues until 6 years of age. Both 5α-R1 and 5α-R2
proteins were expressed in prostatic epithelial and stromal
components, at consistent levels throughout all age groups.
5α-R1 is expressed mainly in the epithelium and 5α-R2 is
expressed mainly in the stroma of the prostate. At the mRNA
levels, both are detectable throughout the ages studied and
both peak in the second trimester.
9.1.2. Newborn-Onset of Puberty. In newborns, 5α-R1 is
expressed at the protein level in the liver, skin, scalp [13]
and prostate [55]. 5α-R2 is expressed in prostate, seminal
vesicles, epididymis, liver, and to lesser extent in scalp and
skin [13]. Hepatic expression of 5α-R1 and 2 is present at the
protein level (immunoblotting) throughout postnatal life. At
approximately 1.5 years, the expression of both proteins is
not detected in the skin and scalp until the onset of puberty.
At puberty, only 5α-R1 is reexpressed in the skin and scalp
and persists thereafter until 81 years. In the prostate gland,
Lunacek et al. reported that both 5α-R1 and 5α-R2 were
detectable at the protein level using IHC until approximately
1 year of age. After that, they were detectable at the mRNA
level (RT-PCR) until 6 years of age. Thigpen et al. only
detected 5α-R2 at the protein level using immunoblotting in
prostatic tissue from a 7-year-old male. Since the methods
used by this group did not detect 5α-R1 protein in the
newborn, juvenile, or adult prostatic tissues, and since other
groups detected 5α-R1 at the protein level in fetal and
adult benign prostatic tissue, 5α-R1 and 5α-R2 appear to
be expressed in the prostate in male fetuses and throughout
postnatal life.
9.1.3. Adulthood-Old Age. 5α-R1-3 is ubiquitously expressed
[10, 11, 13, 20, 55]. 5α-R1 and 5α-R2 are expressed
diﬀerently in liver, genital and nongenital skin, prostate,
epididymis, seminal vesicle, testis, ovary, uterus, kidney,
exocrine pancreas, and brain (Table 2, Aumuller et al.). Our
laboratory described the expression of 5α-R3 using IHC in
variousbenignandmalignanttissues.5α-R3isoverexpressed
particularly in lung adenocarcinoma, testicular seminoma
and yolk sac tumors, papillary thyroid cancer, and androgen-
stimulated and castration-recurrent CaP relative to their
benign counterparts [20]. When contrasting these data with
the expressed sequence tag (EST) database from NCBI, both
sets of data suggest a broad pattern of expression for 5α-R1-3
in human tissues; ESTs for 5α-R1 (271 sequences) have been
reported from diﬀerent human tissues, which include lung,
brain, intestine, skin, prostate, testis, and stomach [56]. ESTs
for 5α-R2 (39 sequences) have been reported in prostate,
lung, liver, kidney, brain, testis, and skin [57]. ESTs for 5α-
R3 (149 sequences) have been reported in kidney, testis,
intestine, brain, liver, uterus, pancreas, skin, and prostate
[58]. Tissue distribution of 5α-R3 protein in several human
benign tissues was consistent with the tissue origin of the 5α-
R3 EST reported at NCBI [20].
9.2. According to Organs. (See [10–13, 15–20, 54–61]
(Table 3).)8 Advances in Urology
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o
p
s
y
a
n
d
s
u
r
g
i
c
a
l
t
i
s
s
u
e
s
a
m
p
l
e
s
M
e
s
s
e
n
g
e
r
R
N
A
(
N
B
)
a
n
d
p
r
o
t
e
i
n
e
x
p
r
e
s
s
i
o
n
(
I
H
C
a
n
d
W
B
)
u
s
i
n
g
r
a
b
b
i
t
p
o
l
y
c
l
o
n
a
l
a
n
t
i
b
o
d
i
e
s
a
g
a
i
n
s
t
p
e
p
t
i
d
e
s
f
r
o
m
C
-
t
e
r
m
i
n
u
s
p
a
r
t
s
o
f
5
α
-
R
1
-
2
5
α
-
R
1
p
r
o
t
e
i
n
i
s
e
x
p
r
e
s
s
e
d
i
n
l
i
v
e
r
a
n
d
c
h
e
s
t
s
k
i
n
a
n
d
5
α
-
R
1
m
R
N
A
w
a
s
d
e
t
e
c
t
e
d
i
n
c
e
r
e
b
e
l
l
u
m
,
h
y
p
o
t
h
a
l
a
m
u
s
,
p
o
n
s
,
m
e
d
u
l
l
a
o
b
l
o
n
g
a
t
a
,
s
k
i
n
,
a
n
d
l
i
v
e
r
5
α
-
R
1
w
a
s
n
o
t
d
e
t
e
c
t
e
d
b
y
W
B
i
n
a
n
y
f
e
t
a
l
t
i
s
s
u
e
.
5
α
-
R
1
w
a
s
d
e
t
e
c
t
e
d
b
y
W
B
i
n
n
e
w
b
o
r
n
l
i
v
e
r
,
s
k
i
n
,
a
n
d
s
c
a
l
p
.
5
α
-
R
1
w
a
s
d
e
t
e
c
t
e
d
b
y
W
B
i
n
a
l
l
s
c
a
l
p
s
a
m
p
l
e
s
f
r
o
m
b
a
l
d
i
n
g
a
n
d
n
o
n
b
a
l
d
i
n
g
m
e
n
(
e
x
c
e
p
t
o
n
e
)
.
I
t
w
a
s
n
o
t
d
e
t
e
c
t
e
d
i
n
a
n
y
n
o
r
m
a
l
p
r
o
s
t
a
t
e
,
B
P
H
,
o
r
P
C
s
a
m
p
l
e
5
α
-
R
2
p
r
o
t
e
i
n
i
s
e
x
p
r
e
s
s
e
d
i
n
p
r
o
s
t
a
t
e
,
s
e
m
i
n
a
l
v
e
s
i
c
l
e
s
,
e
p
i
d
i
d
y
m
i
s
,
a
n
d
l
i
v
e
r
.
5
α
-
R
2
m
R
N
A
w
a
s
d
e
t
e
c
t
e
d
i
n
p
r
o
s
t
a
t
e
,
S
V
,
e
p
i
d
i
d
y
m
i
s
.
a
n
d
l
i
v
e
r
.
5
α
-
R
2
w
a
s
d
e
t
e
c
t
e
d
b
y
W
B
o
n
l
y
i
n
f
e
t
a
l
g
e
n
i
t
a
l
s
k
i
n
(
n
o
t
d
e
t
e
c
t
e
d
i
n
f
e
t
a
l
l
i
v
e
r
,
a
d
r
e
n
a
l
,
t
e
s
t
i
s
,
o
v
a
r
y
,
s
c
a
l
p
,
a
n
d
b
r
a
i
n
)
.
5
α
-
R
2
w
a
s
d
e
t
e
c
t
e
d
b
y
W
B
i
n
n
e
w
b
o
r
n
p
r
o
s
t
a
t
e
,
S
V
,
e
p
i
d
i
d
y
m
i
s
,
l
i
v
e
r
,
s
k
i
n
.
a
n
d
s
c
a
l
p
.
5
α
-
R
2
w
a
s
n
o
t
d
e
t
e
c
t
e
d
b
y
W
B
i
n
a
n
y
s
a
m
p
l
e
o
f
b
a
l
d
i
n
g
a
n
d
n
o
n
b
a
l
d
i
n
g
s
c
a
l
p
f
r
o
m
o
n
e
m
a
n
.
I
t
w
a
s
d
e
t
e
c
t
e
d
i
n
a
l
l
n
o
r
m
a
l
p
r
o
s
t
a
t
e
,
B
P
H
,
a
n
d
P
C
s
a
m
p
l
e
s
5
α
-
R
1
p
r
o
t
e
i
n
w
a
s
n
o
t
d
e
t
e
c
t
e
d
i
n
a
n
y
p
r
o
s
t
a
t
e
s
a
m
p
l
e
T
h
o
m
a
s
e
t
a
l
.
[
1
4
]
5
α
-
R
1
-
2
P
r
o
s
t
a
t
e
:
B
P
H
(
T
U
R
P
)
,
A
S
C
a
P
(
R
P
)
,
C
a
P
m
e
t
a
s
t
a
s
i
s
i
n
a
n
d
r
o
g
e
n
d
e
p
r
i
v
a
t
i
o
n
-
t
r
e
a
t
e
d
m
e
n
(
a
u
t
o
p
s
y
)
P
r
o
t
e
i
n
e
x
p
r
e
s
s
i
o
n
(
I
H
C
)
u
s
i
n
g
r
a
b
b
i
t
p
o
l
y
c
l
o
n
a
l
a
n
t
i
b
o
d
i
e
s
a
g
a
i
n
s
t
p
e
p
t
i
d
e
s
f
r
o
m
N
-
t
e
r
m
i
n
u
s
o
f
5
α
-
R
1
-
2
p
r
o
t
e
i
n
s
.
A
n
t
i
b
o
d
y
s
p
e
c
i
ﬁ
c
i
t
y
c
o
n
ﬁ
r
m
e
d
w
i
t
h
W
B
o
n
n
a
¨
ı
v
e
,
5
α
-
R
1
-
a
n
d
5
α
-
R
2
-
t
r
a
n
s
f
e
c
t
e
d
C
O
S
-
1
c
e
l
l
s
a
n
d
I
H
C
o
n
t
r
a
n
s
f
e
c
t
e
d
C
O
S
-
1
c
e
l
l
s
-
E
v
a
l
u
a
t
e
d
b
y
m
e
a
s
u
r
i
n
g
p
e
r
c
e
n
t
a
g
e
o
f
m
o
d
e
r
a
t
e
-
a
n
d
h
i
g
h
-
i
n
t
e
n
s
i
t
y
i
m
m
u
n
o
s
t
a
i
n
i
n
g
a
r
e
a
s
i
n
r
e
l
a
t
i
o
n
t
o
t
o
t
a
l
e
p
i
t
h
e
l
i
a
l
,
P
I
N
,
o
r
t
u
m
o
r
a
r
e
a
i
n
P
E
t
i
s
s
u
e
s
N
u
c
l
e
a
r
i
n
B
P
H
,
s
h
i
f
t
s
t
o
c
y
t
o
p
l
a
s
m
i
n
H
G
P
I
N
a
n
d
C
a
P
I
m
m
u
n
o
s
t
a
i
n
i
n
g
i
n
t
e
n
s
i
t
y
:
M
e
t
a
s
t
a
s
i
s
>
C
R
-
C
a
P
>
A
S
-
C
a
P
=
H
G
P
I
N
>
B
P
H
M
a
i
n
l
y
c
y
t
o
p
l
a
s
m
i
c
i
n
a
l
l
s
p
e
c
i
m
e
n
s
I
m
m
u
n
o
s
t
a
i
n
i
n
g
i
n
t
e
n
s
i
t
y
:
B
P
H
=
M
e
t
a
s
t
a
s
i
s
=
C
R
-
C
a
P
>
A
S
-
C
a
P
=
H
G
P
I
N
A
l
l
d
i
ﬀ
e
r
e
n
c
e
s
a
r
e
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
ﬁ
c
a
n
t10 Advances in Urology
T
a
b
l
e
3
:
C
o
n
t
i
n
u
e
d
.
A
u
t
h
o
r
i
s
o
z
y
m
e
s
s
t
u
d
i
e
d
T
i
s
s
u
e
t
y
p
e
M
a
t
e
r
i
a
l
s
a
n
d
m
e
t
h
o
d
s
5
α
-
R
1
5
α
-
R
2
N
o
t
e
s
T
h
o
m
a
s
e
t
a
l
.
[
1
4
]
5
α
-
R
1
-
2
P
r
o
s
t
a
t
e
:
A
S
-
C
a
P
(
R
P
)
w
i
t
h
G
l
e
a
s
o
n
s
c
o
r
e
<
7
,
7
,
>
7
P
r
o
t
e
i
n
e
x
p
r
e
s
s
i
o
n
(
I
H
C
)
u
s
i
n
g
v
a
l
i
d
a
t
e
d
r
a
b
b
i
t
p
o
l
y
c
l
o
n
a
l
a
n
t
i
b
o
d
i
e
s
,
e
v
a
l
u
a
t
e
d
b
y
v
i
s
u
a
l
l
y
e
s
t
i
m
a
t
i
n
g
p
e
r
c
e
n
t
o
f
t
o
t
a
l
t
u
m
o
r
a
r
e
a
s
h
o
w
i
n
g
l
o
w
-
,
m
o
d
e
r
a
t
e
,
a
n
d
h
i
g
h
-
i
n
t
e
n
s
i
t
y
i
n
r
e
l
a
t
i
o
n
t
o
G
l
e
a
s
o
n
s
c
o
r
e
M
a
i
n
l
y
n
u
c
l
e
a
r
i
n
B
P
H
,
n
u
c
l
e
a
r
a
n
d
c
y
t
o
p
l
a
s
m
i
c
i
n
C
a
P
(
a
l
l
g
r
a
d
e
s
)
,
a
n
d
i
n
a
d
j
a
c
e
n
t
b
e
n
i
g
n
e
p
i
t
h
e
l
i
a
l
t
i
s
s
u
e
I
m
m
u
n
o
s
t
a
i
n
i
n
g
i
n
t
e
n
s
i
t
y
:
H
i
g
h
g
r
a
d
e
>
m
o
d
e
r
a
t
e
g
r
a
d
e
=
l
o
w
g
r
a
d
e
>
P
C
-
a
d
j
a
c
e
n
t
b
e
n
i
g
n
t
i
s
s
u
e
>
B
P
H
M
a
i
n
l
y
c
y
t
o
p
l
a
s
m
i
c
i
n
a
l
l
s
a
m
p
l
e
s
(
b
e
n
i
g
n
a
n
d
m
a
l
i
g
n
a
n
t
)
I
m
m
u
n
o
s
t
a
i
n
i
n
g
i
n
t
e
n
s
i
t
y
:
B
P
H
>
h
i
g
h
g
r
a
d
e
>
m
o
d
e
r
a
t
e
g
r
a
d
e
=
l
o
w
g
r
a
d
e
=
a
d
j
a
c
e
n
t
b
e
n
i
g
n
t
i
s
s
u
e
S
t
a
i
n
i
n
g
i
n
C
a
P
-
a
d
j
a
c
e
n
t
b
e
n
i
g
n
t
i
s
s
u
e
i
s
n
o
t
s
i
g
n
i
ﬁ
c
a
n
t
y
d
i
ﬀ
e
r
e
n
t
f
r
o
m
l
o
w
-
a
n
d
h
i
g
h
-
g
r
a
d
e
C
a
P
f
o
r
e
i
t
h
e
r
i
s
o
z
y
m
e
S
¨
o
d
e
r
s
t
¨
o
m
e
t
a
l
.
[
1
5
]
5
α
-
R
1
-
2
P
r
o
s
t
a
t
e
:
B
P
H
(
T
U
R
P
)
a
n
d
A
S
-
C
a
P
v
i
a
R
P
o
r
R
C
M
e
s
s
e
n
g
e
r
R
N
A
e
x
p
r
e
s
s
i
o
n
(
s
q
R
T
-
P
C
R
)
a
n
d
m
e
a
s
u
r
e
m
e
n
t
o
f
5
α
-
R
e
n
z
y
m
e
a
c
t
i
v
i
t
y
a
t
p
H
5
.
5
a
n
d
7
u
s
i
n
g
1
4
C
-
T
a
t
3
7
◦
C
i
n
h
o
m
o
g
e
n
i
z
e
d
f
r
o
z
e
n
p
u
l
v
e
r
i
z
e
d
p
r
o
s
t
a
t
e
t
i
s
s
u
e
5
α
-
R
1
m
R
N
A
e
x
p
r
e
s
s
i
o
n
i
s
s
i
m
i
l
a
r
i
n
B
P
H
a
n
d
A
S
-
C
a
P
.
T
h
e
r
e
w
a
s
n
o
c
o
r
r
e
l
a
t
i
o
n
b
e
t
w
e
e
n
e
n
z
y
m
e
a
c
t
i
v
i
t
y
a
t
p
H
(
5
.
5
a
n
d
7
)
a
n
d
5
α
-
R
1
m
R
N
A
e
x
p
r
e
s
s
i
o
n
a
s
e
x
p
r
e
s
s
e
d
o
n
t
h
e
b
a
s
i
s
o
f
β
-
a
c
t
i
n
5
α
-
R
2
m
R
N
A
a
n
d
e
n
z
y
m
e
a
c
t
i
v
i
t
y
w
e
r
e
h
i
g
h
e
r
i
n
B
P
H
t
h
a
n
i
n
A
S
-
C
a
P
.
T
h
e
r
e
w
a
s
a
p
o
s
i
t
i
v
e
c
o
r
r
e
l
a
t
i
o
n
b
e
t
w
e
e
n
e
n
z
y
m
e
a
c
t
i
v
i
t
y
a
t
p
H
5
.
5
a
n
d
e
x
p
r
e
s
s
i
o
n
o
f
5
α
-
R
2
m
R
N
A
a
s
e
x
p
r
e
s
s
e
d
o
n
t
h
e
b
a
s
i
s
o
f
β
-
a
c
t
i
n
L
e
h
l
e
e
t
a
l
.
[
6
1
]
5
α
-
R
1
-
2
B
P
H
a
n
d
C
a
P
t
i
s
s
u
e
p
o
s
t
p
r
o
s
t
a
t
e
b
i
o
p
s
y
o
r
R
P
f
r
o
z
e
n
i
n
l
i
q
u
i
d
n
i
t
r
o
g
e
n
,
o
n
e
h
u
m
a
n
l
i
v
e
r
s
a
m
p
l
e
M
e
s
s
e
n
g
e
r
R
N
A
e
x
p
r
e
s
s
i
o
n
(
I
S
H
,
s
q
R
T
-
P
C
R
)
I
S
H
s
h
o
w
e
d
t
h
a
t
5
α
-
R
1
m
R
N
A
i
s
e
x
p
r
e
s
s
e
d
i
n
e
p
i
t
h
e
l
i
u
m
>
s
t
r
o
m
a
m
R
N
A
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
s
b
y
s
q
R
T
-
P
C
R
:
l
i
v
e
r
>
C
a
P
>
B
P
H
>
N
o
r
m
a
l
p
r
o
s
t
a
t
e
I
S
H
s
h
o
w
e
d
t
h
a
t
5
α
-
R
2
m
R
N
A
i
s
e
x
p
r
e
s
s
e
d
i
n
e
p
i
t
h
e
l
i
u
m
>
s
t
r
o
m
a
m
R
N
A
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
s
b
y
s
q
R
T
-
P
C
R
:
l
i
v
e
r
=
B
P
H
>
N
o
r
m
a
l
p
r
o
s
t
a
t
e
>
C
a
P
H
a
b
i
b
e
t
a
l
.
[
1
6
]
5
α
-
R
1
-
2
B
P
H
t
i
s
s
u
e
(
T
U
R
P
)
f
r
o
z
e
n
i
n
l
i
q
u
i
d
n
i
t
r
o
g
e
n
o
r
i
n
i
c
e
-
c
o
l
d
R
P
M
I
w
i
t
h
F
B
S
a
n
d
a
r
c
h
i
v
a
l
P
E
-
B
P
H
t
i
s
s
u
e
M
e
s
s
e
n
g
e
r
R
N
A
e
x
p
r
e
s
s
i
o
n
(
I
S
H
,
R
T
-
P
C
R
)
a
n
d
m
e
a
s
u
r
e
m
e
n
t
o
f
e
n
z
y
m
e
a
c
t
i
v
i
t
y
a
t
p
H
5
a
n
d
7
.
5
u
s
i
n
g
3
H
-
T
a
t
3
7
◦
C
i
n
h
o
m
o
g
e
n
i
z
e
d
p
u
l
v
e
r
i
z
e
d
f
r
o
z
e
n
p
r
o
s
t
a
t
e
t
i
s
s
u
e
5
α
-
R
1
m
R
N
A
e
x
p
r
e
s
s
e
d
i
n
e
p
i
t
h
e
l
i
u
m
>
s
t
r
o
m
a
5
α
-
R
1
m
R
N
A
e
x
p
r
e
s
s
e
d
i
n
e
p
i
t
h
e
l
i
u
m
>
s
t
r
o
m
a
5
α
-
R
2
m
R
N
A
>
5
α
-
R
1
m
R
N
A
i
n
B
P
H
5
α
-
R
2
e
n
z
y
m
e
a
c
t
i
v
i
t
y
 
5
α
-
R
1
e
n
z
y
m
e
a
c
t
i
v
i
t
y
i
n
h
o
m
o
g
e
n
i
z
e
d
B
P
H
t
i
s
s
u
e
B
o
n
k
h
o
ﬀ
e
t
a
l
.
[
1
7
]
5
α
-
R
1
-
2
B
P
H
(
T
U
R
P
)
,
A
S
-
C
a
P
(
R
P
)
,
C
R
-
C
a
P
(
c
h
a
n
n
e
l
i
n
g
T
U
R
)
P
r
o
t
e
i
n
e
x
p
r
e
s
s
i
o
n
(
I
H
C
)
u
s
i
n
g
p
o
l
y
c
l
o
n
a
l
r
a
b
b
i
t
a
n
t
i
b
o
d
i
e
s
a
g
a
i
n
s
t
p
e
p
t
i
d
e
s
f
r
o
m
C
-
t
e
r
m
i
n
u
s
p
a
r
t
s
o
f
5
α
-
R
1
a
n
d
2
,
v
a
l
i
d
a
t
e
d
b
y
E
L
I
S
A
a
n
d
W
B
M
a
i
n
l
y
n
u
c
l
e
a
r
,
i
n
n
o
r
m
a
l
p
r
o
s
t
a
t
e
a
n
d
B
P
H
t
i
s
s
u
e
(
l
u
m
i
n
a
l
e
p
i
t
h
e
l
i
a
l
>
b
a
s
a
l
)
a
n
d
i
n
s
t
r
o
m
a
5
α
-
R
1
i
m
m
u
n
o
s
t
a
i
n
i
n
g
>
5
α
-
R
2
i
n
B
P
H
(
i
n
b
o
t
h
e
p
i
t
h
e
l
i
u
m
a
n
d
s
t
r
o
m
a
)
.
I
n
C
a
P
,
5
α
-
R
1
i
m
m
u
n
o
s
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10. ClinicalRole of 5α-R
Alterations in the conversion of T into DHT by the enzyme
5α-R are associated with a number of human disorders:
10.1. 5α-R2 Deﬁciency (Pseudovaginal Perineoscrotal Hypo-
spadias) [3, 62]. Studies in rabbit, rat, and human fetuses
have shown that 5α-R activity is present in the urogenital
sinus and external genital anlage prior to prostate and
external genital diﬀerentiation. However, 5α-R activity is not
present in the Wolﬃan duct, at the time of epididymal,
vas deferens, and seminal vesicle diﬀerentiation. Thus, T
and DHT have selective roles in male sexual diﬀerentiation
duringembryogenesis.TmediatesWolﬃanductaldiﬀerenti-
ation,whileDHTmediatesmaleexternalgenitalandprostate
diﬀerentiation.
5α-R2 deﬁciency is caused by decreased synthesis of
DHT due to mutations in the 5α-reductase 2 gene. At
least 50 mutations have been reported and is autosomal-
recessive in the majority of patients. 5α-R2 deﬁciency results
in a 46,XY disorder of sexual development (formerly male
pseudohermaphroditism). Aﬀected males are born with
normal male internal reproductive structures (epididymis,
seminal vesicles, and vasa deferentia); however, their external
genitalia resemble those of females, that is, ambiguous
genitalia. These individuals have a small penis that resembles
an enlarged clitoris, labioscrotal fusion, and a urogenital
sinus in which there are two separate urethral and vaginal
openings. The vagina is short and blind ending. The testes
are either in the labia, or inguinal canals or intra-abdominal.
The vasa terminate at the blind-ending vaginal pouch. The
prostate is hypoplastic, nonpalpable on rectal examination
and is found to be rudimentary on transrectal ultrasound
and MRI. Prostatic volumes are approximately (1/10)th
of age-matched normal controls. Prostate biopsy reveals
ﬁbrousconnectivetissue,smoothmuscle,andnoidentiﬁable
epithelial tissue, which suggests atrophic epithelium or lack
of epithelial diﬀerentiation. Plasma PSA is low or unde-
tectable in these patients. Administration of DHT results
in enlargement of the prostate. Neither BPH nor CaP has
been reported in these patients. At puberty, these individuals
undergopartialvirilizationoftheexternalgenitalia,although
their secondary sexual hair remains sparse and they develop
less male pattern baldness and acne despite normal sebum
production. They undergo an increase in muscle mass,
phallic growth, development of male body habitus, and
deepening of the voice. Their libido is normal and they
are capable of erections. Sperm production and fertility
have been reported but depend on testicular location. The
mechanism of partial virilization atpuberty is througheither
the androgen receptor binding very high levels of serum T,
albeit at lower aﬃnity, or the increased expression of skin
5α-R1 at puberty, which results in peripheral synthesis of
DHT from T or via the action of 5α-R3 through unknown
mechanisms. 5α-R1 gene is normal in these subjects. No
genetic deﬁciencies of the type 1 enzyme have yet been
reported. Inactivation of the 5α- R 1g e n ei nm i c ea d v e r s e l y
aﬀected reproduction in females. In addition, mice deﬁcient
in 5α-R1 manifest a parturition defect that is not reversed
by the administration of DHT, but is reversed by 3α-an-
drostanedioltreatment.Thebiochemicalfeaturesofthissyn-
drome include the following:
(a) high normal to elevated levels of plasma T,
(b) low normal to decreased levels of plasma DHT,
(c) increased T to DHT ratio at baseline and following
hCG stimulation,
(d) normal metabolic clearance of T and DHT,
(e) decreased levels of urinary 5α-reduced metabolites of
C19 and C21 steroids, with increased 5β/5α urinary
metabolite ratios,
(f) decreased plasma and urinary 3α-androstanediol
glucuronide, a major metabolite of DHT,
(g) increased plasma levels of LH and/or FSH.
Phenotype, development and reproductive function in
human females with 5α-R2 deﬁciency are unaﬀected.
10.2. LUTS Attributed to BPE. BPE results in a signiﬁcant
morbidity due to urethral obstruction and secondary detru-
sor dysfunction. Histological evidence of BPH is found in
50% of males by the age of 50 and 90% of males by
the age of 80 [63]. The development of BPH depends
on androgens, and BPH does not occur in men castrated
prior to puberty [64]. 5α-R isozymes play signiﬁcant roles
in BPH development since DHT is the major androgen
in the prostate. Patients with decreased DHT production
due to 5α-R2 deﬁciency have a small prostate and BPH
has not been reported [4]. In castrated dogs, treatment
with either DHT or T results increased intraprostatic DHT
and BPH [65]. However, coadministration of T with a
5α-R inhibitor decreased DHT formation and prevented
BPH [66]. Finasteride and dutasteride have been shown
to decrease circulating and intraprostatic DHT by 60–
90%, and 90–98%, respectively [48–52]. Finasteride and
dutasteride result in a decrease in prostate size by 20–25%
through prostatic epithelial cell apoptosis and a signiﬁcant
improvementinLUTS.Furthermore,theychangethenatural
history of the disease by decreasing the risk of acute urinary
retention by 57–79% and decreasing BPH-related surgery by
48–69% [67, 68]. Although both isozymes are overexpressed
in prostate tissues from patients with BPH [15], inhibition
of 5α-R2 activity is the major contributor in the treatment
of BPH as the additional inhibition of 5α-R1 activity by
dutasteride does not appear to be of any further beneﬁt in
BPH treatment [69].
10.3. Primary Prevention of CaP [67, 68]. Both ﬁnasteride
and dutasteride have been tested in large, prospective,
randomized, placebo-controlled, double-blind studies as
primary preventive therapies for CaP. The Prostate Cancer
Prevention Trial (PCPT) randomized nearly 19,000 men at
low risk for CaP into a treatment group, given ﬁnasteride
at 5mg/d and a control group, given placebo, who were
followed up for 7 years. At the end of the study, participants
were oﬀered a prostate biopsy. For-cause biopsies were doneAdvances in Urology 13
Table 4: Comparison between PCPT and REDUCE.
PCPT REDUCE
Sponsor South West Oncology Group GalxoSmithKline
Duration 7 years 4 years
Risk of CaP in participants lower higher
No. of participants 18,882 randomized
9060 included in ﬁnal analysis 8122 randomized
Age ≥55 years 50–75 years
Entry serum PSA ≤3.0ng/mL 2.5–10ng/mL
Baseline biopsies No Yes (6–12 cores) within 6 months prior to
enrollment
Study-mandated biopsies Year 7 Years 2 and 4
Study-mandated biopsy cores ≥6 (6 cores in nearly 80%) 10 (83% had at least 1 biopsy)
Overall relative risk reduction in CaP
versus placebo 25% 23%
Incidence of Gleason sum ≥7C a P
↑26% (6.4% in ﬁnasteride versus 5.1% in
placebo), P<0.05 Same (6.7% in dutasteride versus 6.8%: in placebo)
Incidence of Gleason sum ≥8C a P
↑91% (2.1% in ﬁnasteride versus 1.1% in
placebo), P<0.05
Same over 4 years (0.9% in dutasteride versus 0.6%
in placebo); however, in years 3-4, there were 12 GS
≥8 CaP in dutasteride group (0.5%) versus 1 in
placebo group (<0.1%), P<0.05
for abnormal DRE and/or PSA > 4.0ng/mL. PCPT showed
that ﬁnasteride was eﬀective at reducing the overall risk of
biopsydetectableCaPbynearly25%andthiswasduemainly
to reduction in the risk of low-grade disease (Gleason sum
<7). The reduction in the risk of CaP was seen across all
subgroups, such as age, race, family history, and baseline
PSA. Finasteride users also had improved BPH outcomes.
The beneﬁts of ﬁnasteride treatment occurred at the expense
of a higher rate of diagnosis of moderate- and high-grade
CaP (Gleason score ≥7) and more sexual adverse eﬀects.
The Reduction by Dutasteride of Prostate Cancer Events trial
(REDUCE) studied the eﬀect of dutasteride versus placebo
in a large group of men at higher risk of CaP than in
PCPT who had at least one negative prostate biopsy at
baseline. The study lasted 4 years and participants received
mandatory prostate biopsy at 2 and 4 years. Dutasteride
decreased the risk of biopsy detectable CaP by nearly 24%
and this reduction in risk was evident across all subgroups
tested. The frequency of diagnosis of moderate- and high-
grade CaP was unchanged over the entire length of the
studyandbeneﬁcialeﬀectswereobserved onBPHoutcomes.
However, 12 Gleason score 8–10 cancers were detected in
the dutasteride group at years 3-4 versus only one in the
placebo groupand dutasteridetreatmentwasassociated with
more sexual adverse eﬀects. The beneﬁt of ﬁnasteride or
dutasteride in reducing the risk of low-grade CaP is clear.
Low-grade CaP is unlikely to be lethal and patients may
reduce their risk of overtreatment. However, these drugs
may induce high-grade CaP, a concern that has prevented
FDA approval of ﬁnasteride and dutasteride use for CaP
prevention. Several secondary analyses of these two trials
have concluded that these drugs actually reduce the risk
of moderate- and high-grade disease but these analyses are
hypothesis-generating and not deﬁnitive. In March 2009, the
American Urological Association and the American Cancer
Society issued a “cautious” joint statement that accepted
these drugs as an option to prevent CaP provided that
they are used mainly after a thorough discussion of risks
and beneﬁts. In January 2011, the FDA’s Oncologic Drug
Advisory Committee voted against recommending either
dutasteride or ﬁnasteride for the speciﬁc indication of CaP
riskreductionbecauseofthepotentialincreasedriskofhigh-
grade disease. Table 4 provides a comparison between PCPT
and REDUCE.
10.4. Treatment of CaP
(a) Biochemical Failure after Local Therapy with Curative
Intent [70–73]. Finasteride and dutasteride have been tried,
singly and in combination, in patients with biochemical fail-
ure after radical prostatectomy or radiotherapy. The most
common combination was a 5α-RI and a nonsteroidal an-
tiandrogen. Finasteride and dutasteride monotherapy de-
creasedserumPSAtovariableextent.PSAdecreasewasmore
frequent and of greater magnitude in patients treated with
an antiandrogen and 5α- R Iv e r s u s5 α-RI alone. However,
none of these trials studied the impact on disease-speciﬁc
or overall survival and none compared 5α-RI mono- or
combination therapy against 1st line androgen deprivation
treatment in a randomized fashion.
(b) CR-CaP. CR-CaP was thought for many years to be
androgen-independent or hormone-refractory but CR-CaP
remains AR-dependent and probably AR-ligand dependent
in almost all cases [74]. Despite castrate serum levels of
T( <50ng/dL), CR-CaP tissue levels of T and DHT were
similar and 80–90% lower compared to their levels in benign14 Advances in Urology
prostatic tissue, respectively [75]. CR-CaP tissue synthesizes
testicular androgens (T and DHT) in an intracrine fashion
from several substrates such as cholesterol, progesterone,
adrenal androgens, and androstandione [76–79]. Other phe-
nomena intrinsically acquired by CR-CaP tissue in response
to castration include the continuous expression of AR
[80], upregulation of the synthesis of enzymes necessary
for steroidogenesis [76], AR hypersensitivity (up to 10,000
times) to low levels of ligands by alteration of its co-activator
proﬁle from SRC1 to TIF2 and through its phosphorylation
bySRCandAck1tyrosinekinases[81–83]andARfunctional
mutations, which broaden ligand speciﬁcity in 5–30% of
cases [84].
New second-line hormonal therapeutic agents that have
shown better performance in CR-CaP compared to the
old generation of second-line hormonal therapies are abi-
raterone acetate and MDV3100, among others [77, 85].
Abiraterone acetate is a potent, selective, and irreversible
inhibitor of CYP17A1 enzyme, which is an important
enzyme in the intracrine synthesis of testicular androgens.
MDV3100 inhibits ligand binding to the AR and nuclear
translocation of AR-ligand complex. The clinical response
to these new drugs is indirect proof that CR-CaP remains
androgen stimulated. 5α-R isozymes are important in the
growth of CR-CaP tissue since they are upregulated in CR-
CaP and may contribute to intracrine synthesis of testicular
androgens.Theseenzymesconvertprogesterone,ASD,andT
into pregnanldione, androstandione, and DHT, respectively
[74, 79]. Pregnanldione is further converted via several steps
into androstandiol which is oxidized by 17β-hydroxysteroid
dehydrogenase 2 and 10 (17β-HSD2 and 10) to DHT (the
backdoor pathway to DHT synthesis). Androstandione is
converted by 17βHSD3 into DHT.
Clinical trials of ﬁnasteride [70] and dutasteride [71]a s
monotherapy in patients with advanced CaP showed no
improvement of clinical end points. The presence of 5α-R3
in CR-CaP is a potential explanation, until such time that an
inhibitor has been proven eﬀective clinically. Combination
therapy of 5α-RI with antiandrogen or ketoconazole and
hydrocortisone was tried in CR-CaP as second or third line
hormonal therapies [86–89]. PSA decreases of variable mag-
nitudes and durations were achieved in more than half
the patients. However, none of the combination trials were
designed to test the eﬀect on disease-speciﬁc and overall sur-
vival. In a phase II, single arm study of 57 patients with CR-
CaP, dutasteride added to ketoconazole, and hydrocortisone
reduced PSA ≥ 50% of baseline value in 56% of patients,
responsesthatlastedforamedianof20months.Mediantime
to disease progression was 14.5 months that was better than
all prior studies of ketoconazole and hydrocortisone in CR-
CaP [89].
10.5. Androgen-Stimulated Skin Disorders (Acne, Androgenic
Alopecia and Hirsutism). Hyperandrogenism, or excessive
androgen production, is primarily a disorder of females.
Polycystic ovary syndrome (PCOS) is the most common
cause of female hyperandrogenism with a prevalence of 6%
to 10% in women of childbearing age [90]. Other causes
of hyperandrogenism include androgen-secreting ovarian
and adrenal tumors, congenital adrenal hyperplasia, and
exogenous androgenic hormone administration. Regardless
of the cause, overproduction of either T or T precursors
leads to exaggerated T action in target tissues such as skin. In
skin, T is converted to DHT by the enzyme 5α-R, which acts
directly on hair follicles and the sebaceous glands. The most
frequent dermatologic manifestations of androgen excess are
hirsutism, acne, and androgenic alopecia [91].
Androgen surge can miniaturize hair follicles resulting
in male androgenic alopecia at puberty and in the scalp
of genetically predisposed individuals. In women, androgen
excess plays a role in scalp hair loss; however, this process
is diﬀerent than in men and is referred to as female pattern
hair loss. Hirsutism is a disorder of excessive growth of
terminal hair in women, in a male-like distribution, which
is stimulated by androgen excess [92]. In acne, the pubertal
androgensurgeincreasesthestimulationofsebaceousglands
resulting in increased sebum production and acne formation
in susceptible individuals [93].
In all androgen-stimulated skin disorders, the activity
of 5α-R enzyme system is increased such as in the hair
follicles of hirsute women [93], in balding scalps [94], and in
acne-prone skin [95]. Inhibition of the 5α-R enzyme system
appears to be a target for treatment of androgen-stimulated
skin disorders, since 5α-R inhibitors mayresultin fewerside-
eﬀects by not blocking the action of T, unlike classical anti-
androgens such as cyproterone acetate or spironolactone.
Finasteride and dutasteride reduce scalp DHT levels by
64% and 51%, respectively [96, 97]. In men with androgenic
alopecia, ﬁnasteride and dutasteride signiﬁcantly increased
hair count after a minimum of 6-month treatment [98, 99].
While ﬁnasteride 1mg daily was superior to 5% topical
minoxidil in inducing hair growth [100], ﬁnasteride 5mg
daily was inferior to dutasteride 2.5mg daily in a phase
II study as treatment for male androgenic alopecia [97].
Finasteride and topical minoxidil (but not dutasteride) are
FDA-approved for male androgenic alopecia. In women
with androgenic alopecia, neither ﬁnasteride nor dutasteride
is FDA-approved treatment options due to teratogenicity.
Finasteride has been tested in postmenopausal women at the
1mg dose without success. However, ﬁnasteride was shown
to be eﬀectivein4womenwithelevatedserumTlevels[101].
Whether ﬁnasteride is only eﬀective in women with hair loss
and hyperandrogenism or that higher doses are needed in
women remains to be tested. A single case report showed
improvement with dutasteride in a woman who had failed
to respond to ﬁnasteride [102].
5α-RIalsoisacceptabletherapyforhirsutism.Finasteride
5mg/day was superior to placebo and similar to spirono-
lactone and ﬂutamide in reducing the severity of hirsutism
[103]; however, in a diﬀerent study, ﬁnasteride was inferior
to ﬂutamide as a treatment for hirsutism [104]. Dutasteride
has not been tested as a treatment for hirsutism.
T h er o l eo f5 α-RI is unclear for treatment of acne. MK-
386, a selective 5α-R1 inhibitor, decreased sebum DHT levels
in a dose-dependent fashion [105]. MK-386 was examined
as a treatment for acne in a placebo-controlled trial and
w a sf o u n dt ob es i m i l a rt op l a c e b oa n di n f e r i o rt os y s -
temic minocycline therapy. Furthermore, MK-386 did notAdvances in Urology 15
enhance the therapeutic beneﬁt of minocycline when used in
combination [106]. In another study, ﬁnasteride decreased
the severity of acne but was inferior to ﬂutamide and
cyproterone acetate with ethinyl estradiol [107]. No studies
of dutasteride for treatment of acne have been reported.
11. Conclusions
The5α-Rsystemisanimportantplayerinhumanphysiology
andpathology.Moreworkisneededtoidentifythebiochem-
ical characteristics and role of 5α-R3 in several human con-
ditions such as CaP and androgen-stimulated skin diseases.
Clinical data are inconclusive regarding the beneﬁt of 5α-RI
for CaP prevention. Clinical trials are ongoing to deﬁne the
role of dutasteride for treatment of CaP, such as REDEEM
(dutasteride in low-risk CaP patients on active surveillance),
ARTS(biochemicalfailureafterlocaltreatmentwithcurative
intent), AVO 108943 (bicalutamide and dutasteride versus
bicalutamide and placebo in CR-CaP), and ARI40006 (2-
year follow-up study of REDUCE participants who received
dutasteride or placebo) [108]. Future trials should focus on
blocking multiple steroidogenic enzymes at once, such as in
men with biochemical failure after local therapy or men with
CR-CaP. Blocking several diﬀerent steps in steroidogenesis
simultaneously may not allow CaP cells time to adjust to loss
of androgen stimulation.
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